Patents Represented by Attorney Parker Highlander, PLLC
-
Patent number: 8350005Abstract: The present invention relates to polypeptide fragments of endolysin Ply511, which recognize and bind listeria irrespective of the serotype but which have no cell wall hydrolysing enzymatic activity. The invention further relates to methods for enrichment, removal, and detection of listeria.Type: GrantFiled: August 23, 2006Date of Patent: January 8, 2013Assignee: bioMérieux S.A.Inventors: Michael Schutz, Maxi Oelschner
-
Patent number: 8338618Abstract: Disclosed herein are novel oleanolic acid derivatives. Methods of preparing these compounds are also disclosed. The oleanolic acid derivatives of this invention may be used for the treatment and prevention of many diseases, including cancer, neurological disorders, inflammation, and pathologies involving oxidative stress.Type: GrantFiled: November 11, 2011Date of Patent: December 25, 2012Assignee: Reata Pharmaceuticals, Inc.Inventors: Xin Jiang, Jack Greiner, Lester L. Maravetz, Stephen S. Szucs, Melean Visnick
-
Patent number: 8338366Abstract: A nanoparticle-polypeptide complex comprising a bioactive polypeptide in association with a nanoparticle, wherein the bioactive polypeptide is modified by the addition of a chemical moiety that facilitates cellular uptake of the protein. The polypeptide can be a protein or a peptide. In some embodiments, the amino acid sequence of the protein or peptide is derived from the amino acid sequence of a tumor suppressor gene product.Type: GrantFiled: March 14, 2006Date of Patent: December 25, 2012Assignee: The Board of Regents of the University of the Texas SystemInventors: Jacki Lin, Ralph B. Arlinghaus, Tong Sun, Lin Ji, Bulent Ozpolat, Gabriel Lopez-Berestein, Jack A. Roth
-
Patent number: 8334239Abstract: A cell-based screen is reported can be used to identify specific receptor-binding compounds in a combinatorial library of peptoids (N-alkylglycine oligomers) displayed on beads. This strategy was applied to the isolation of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)-binding peptoids, which were optimized to create lead compounds with high affinity for VEGFR2. One of these peptoids was shown to be an antagonist of VEGF-VEGFR2 interaction and receptor function.Type: GrantFiled: July 1, 2008Date of Patent: December 18, 2012Assignee: The Board of Regents of the University of Texas SystemInventors: Thomas Kodadek, D. Gomika Udugamasooriya, Rolf Brekken
-
Patent number: 8329636Abstract: The present invention provides methods and kits a) for predicting colorectal cancer patient survival, as well as the survival of patients harboring other invasive cancers where cellular proliferation and carcinogenesis is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and b) for selecting the corresponding treatment options for such patients based on the allelic nucleotide sequence or SNP at position +316 of the ODC1 promoter gene as well as cancer treatment methods, in each case, which include the determination of the ODC1 promoter +316 position genotype, as a means to guide treatment selection.Type: GrantFiled: May 14, 2010Date of Patent: December 11, 2012Assignees: Arizona Board of Regents on Behalf of University of Arizona, The Regents of the University of California, a California CorporationInventors: Eugene Gerner, Jason A. Zell, Christine McLaren, Frank Meyskens, Hoda Anton-Culver, Patricia A. Thompson
-
Patent number: 8329189Abstract: Provided herein are immunoreactive peptides which can selectively bind Ehrlichia-specific anti-p120 or anti-p140 antibodies. Methods and kits utilizing the immunoreactive peptides are also provided. The immunoreactive peptides may be utilized, e.g., for determining whether or not a subject is infected with Ehrlichia chaffeensis or Ehrlichia canis. In certain embodiments, the immunoreactive peptides may be utilized in an ELISA or lateral flow assay.Type: GrantFiled: April 28, 2010Date of Patent: December 11, 2012Assignee: Research Development FoundationInventors: Jere W. McBride, Tian Luo
-
Patent number: 8329393Abstract: The present invention relates to bacteriophage tail proteins and the derivatives and fragments thereof that are capable of binding endotoxins in the absence of bivalent positive ions, especially Ca2+ or Mg2+. Further, the present invention relates to methods for depleting endotoxins from solutions and samples using the bacteriophage tail proteins according to the present invention and to a detection method for endotoxins.Type: GrantFiled: July 12, 2011Date of Patent: December 11, 2012Assignee: Hyglos Invest GmbHInventors: Stefan Miller, Roman Meyer, Renate Grassl, Manfred Biebl, Holger Grallert
-
Patent number: 8329462Abstract: The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise a self-inactivating configuration for biosaftey and promoters such as the EF1? promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the study of hematopoiesis via lentivector-mediated modification of human HSCs.Type: GrantFiled: August 7, 2009Date of Patent: December 11, 2012Assignee: Research Development FoundationInventors: Didier Trono, Patrick Salmon
-
Patent number: 8324177Abstract: The invention provides saponin mixtures and compounds which are isolated from the species Acacia victoriae and methods for their use. These compounds may contain a triterpene moiety, such as acacic or oleanolic acid, to which oligosaccharides and monoterpenoid moieties are attached. The mixtures and compounds have properties related to the regulation of apoptosis and cytotoxicity of cells and exhibit potent anti-tumor effects against a variety of tumor cells.Type: GrantFiled: June 14, 2011Date of Patent: December 4, 2012Assignee: Research Development FoundationInventors: Charles J. Arntzen, Mary E. Blake, Jordan U. Gutterman, Joseph J. Hoffmann, Gamini S. Jayatilake, David T. Bailey
-
Patent number: 8324181Abstract: Synthesis of a target transcript of a gene is selectively increased in a mammalian cell by contacting the cell with a polynucleotide oligomer of 12-28 bases complementary to a region within a target promoter of the gene under conditions whereby the oligomer selectively increases synthesis of the target transcript.Type: GrantFiled: March 30, 2010Date of Patent: December 4, 2012Assignee: Board of Regents, The University of Texas SystemInventors: David R. Corey, David S. Shames, Bethany A. Janowski, John D. Minna
-
Patent number: 8318951Abstract: The present invention relates to screens for compounds that can induce stem cell differentiation. In addition, isoxazoles and sulfonyl hydrazones are identified as general classes of compounds that can induce differentiation of stem cells into cells of neuronal and cardiac fate, respectively.Type: GrantFiled: May 26, 2011Date of Patent: November 27, 2012Assignee: The Board of Regents of the University of Texas SystemInventors: Eric N. Olson, Douglas Frantz, Jenny Hsieh, Steven L. McKnight, Jay Schneider
-
Patent number: 8314137Abstract: The present invention features monocyclic cyanoenone compositions and methods for using the same in the treatment of diseases such as cancer, inflammatory diseases and neurodegenerative diseases.Type: GrantFiled: July 22, 2009Date of Patent: November 20, 2012Assignee: Trustess of Dartmouth CollegeInventors: Tadashi Honda, Emilie David, Dale Mierke
-
Patent number: 8304526Abstract: The present invention regards mutant forms of Bik that comprise anti-cell proliferation and/or pro-apoptotic activities. In particular embodiments, the Bik polypeptides comprise a substitution at Thr33 and Ser35 and, in some embodiments, phosphorylation at these sites is inhibited. In more particular embodiments, these forms are useful for cancer therapy, particularly when administered in combination with liposomes. In embodiments wherein a mutant Bik polynucleotide is administered for cancer therapy, the polynucleotide may be regulated in a tissue-specific manner.Type: GrantFiled: July 2, 2010Date of Patent: November 6, 2012Assignee: The Board of Regents of the University of Texas SystemInventors: Mien-Chie Hung, Yan Li, Yong Wen
-
Patent number: 8304196Abstract: The present invention provides for the simultaneous assessment of a plurality of tissue regions or microregions, the benefit being homogeneity of the sampling, both in terms of tissue content and timing. Discrete regions of a tissue sample, such as those demarcated by microwells formed within the tissue itself or tissue plugs removed from the tissue in a spatially referenced fashion, can be treated with one or more physical or chemical treatments to liberate target molecules of interest. Subsequent analysis of said target molecules by, e.g., mass spectroscopy, permits identification of a variety of biological parameters, including those associated with disease or therapy.Type: GrantFiled: November 9, 2010Date of Patent: November 6, 2012Assignee: Vanderbilt UniversityInventor: Richard Caprioli
-
Patent number: 8298550Abstract: The invention relates to a modified botulinum toxin comprising a natural heavy chain and a modified light chain, characterized in that the modification of the light chain resides in that it comprises (i) an extension of the chain on its N-terminus which has the structure —(C)n-(tag)m-(X)l- in the direction from the N- to the C-terminal end, wherein C represents a cysteine residue, tag represents any tag and X represents the residue of any naturally occurring amino acid, n represents an integer from 1 to 50, m represents 0 or 1, and l represents 0 or an integer from 1 to 50, and in that (ii) at least one of the cysteine residues in the extension of the chain is coupled to at least one chain of PEG.Type: GrantFiled: July 19, 2011Date of Patent: October 30, 2012Assignee: Merz Pharma GmbH & Co. KGaAInventors: Jurgen Frevert, Volker Specht
-
Patent number: 8293111Abstract: Methods and apparatuses for chromatography are provided, using, for example, water as a stationary phase and carbon dioxide as the mobile phase.Type: GrantFiled: May 16, 2011Date of Patent: October 23, 2012Assignee: UTI Limited PartnershipInventor: Kevin B. Thurbide
-
Patent number: 8293498Abstract: The present invention provides methods for the generation of viable reoviruses using only cloned nucleic acid segments representing the RNA segments of the reovirus genome.Type: GrantFiled: December 19, 2007Date of Patent: October 23, 2012Assignee: Vanderbilt UniversityInventors: Terence S. Dermody, Takeshi Kobayashi, James D. Chappell
-
Patent number: 8283458Abstract: The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borrelia, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies.Type: GrantFiled: December 13, 2011Date of Patent: October 9, 2012Assignee: Board of Regents, The University of Texas SystemInventor: Steven J. Norris
-
Patent number: 8278066Abstract: The present invention is directed to fusion proteins that can be used to assay gene transfer and expression both in vitro and in vivo. The fusion proteins contain a reporter protein, e.g. a somatostatin receptor, fused to a second protein, which may be a protein fusion tag. Alternatively, a fusion protein may be fused to a leader sequence. A leader sequence may localize an expressed protein, e.g. localize a fusion protein to the cell membrane. The invention includes nucleic acids encoding the fusion proteins and methods of assaying for gene expression.Type: GrantFiled: September 6, 2011Date of Patent: October 2, 2012Assignee: Board of Regents, The University of Texas SystemInventor: Vikas Kundra
-
Patent number: D668563Type: GrantFiled: March 14, 2011Date of Patent: October 9, 2012Assignee: Zymo Research CorporationInventors: Nikolas M. Isely, Jonathan K. Brown, Marc E. Van Eden